Cardiology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Vic., Australia.
Eur J Clin Invest. 2017 Nov;47(11):860-867. doi: 10.1111/eci.12792. Epub 2017 Oct 16.
Renal denervation (RDN) is facing various challenges to its initial claimed value in hypertension treatment. Major concerns are the choice of the patients and the technical efficacy of the RDN. Different factors have been described as predicting the capacity of RDN to decrease blood pressure. These factors are related to the patients, the procedure and the tools to confirm successful neural ablation. Their use in future trials should help to improve RDN trials understanding and outcomes. This review summarizes the different predictive factors available and their potential benefits in patient selection and in procedure guidance.
肾动脉去神经术(RDN)在高血压治疗中的最初价值面临着各种挑战。主要关注点是患者的选择和 RDN 的技术效果。已经描述了不同的因素,这些因素可预测 RDN 降低血压的能力。这些因素与患者、程序和确认成功神经消融的工具有关。在未来的试验中使用它们将有助于提高对 RDN 试验的理解和结果。本综述总结了现有的不同预测因素及其在患者选择和程序指导中的潜在益处。